Biodegradation of emerging organic pollutant gemfibrozil: Mechanism, kinetics and pathway modelling
Neha Kamal1, Raveendran Sindhu2, Preeti Chaturvedi Bhargava1
1Aquatic Toxicology Laboratory, Environmental Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan, 31, M.G. Marg, Lucknow 226001, Uttar Pradesh, India.
Abstract:
The increasing population has raised the demand for pharmaceutical and personal care products to maintain a good health. Gemfibrozil (GEM), is extensively used as a lipid regulator and is frequently detected in wastewater treatment systems and poses deleterious health and ecological effects. Hence, the current study employing Bacillus sp. N2 reports the degradation of gemfibrozil via co-metabolism in 15 days. The study reported 86 % degradation with GEM (20 mgL-1) using sucrose (150 mgL-1) as a co-substrate; as compared to 42 % without a co-substrate. Further, time-profiling studies of metabolites revealed significant demethylation and decarboxylation reactions during degradation that leads to formation of six (M1, M2, M3, M4, M5, M6) metabolites as by-products. Based on the LC-MS analysis a potential degradation pathway for GEM by Bacillus sp. N2 was proposed. The degradation of GEM has not been reported so far and the study envisages eco-friendly approach to tackle pharmaceutical- active- compounds.
More Related Videos
13:16A Whole Cell Bioreporter Approach to Assess Transport and Bioavailability of Organic Contaminants in Water Unsaturated Systems
Published on: December 24, 2014
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Related Concept Videos
Drug Biotransformation: Overview
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
The drug's acidity or basicity is essential in...
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
